Reported 1 day ago
In February, investors are encouraged to consider Vertex Pharmaceuticals and Moderna as two promising biotech stocks. Vertex has seen strong growth following the FDA approval of its new pain treatment, Journavx, and continues to thrive with its core cystic fibrosis products while expanding its pipeline. Meanwhile, despite recent challenges, Moderna's innovative mRNA platform and pipeline, including a promising cancer vaccine and respiratory virus treatments, suggest long-term potential for recovery and growth.
Source: YAHOO